This study is being done to determine what effects (good and bad) the therapy venetoclax has on this type of cancer (acute lymphoblastic leukemia, also known as ALL). This investigational therapy will be added to what is a standard, liposomal vincristine, to treat relapsed acute lymphoblastic leukemia. It is hoped that venetoclax will help liposomal vincristine work better to kill the ALL, but it has not yet been proven.
Venetoclax and Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell ALL
OPEN TO ACCRUAL